This website uses cookies

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy

International In-house Counsel Journal logoInternational In-house Counsel Journal logo
Back to library search

Creating Efficiencies in Drug Discovery and Development Using Artificial Intelligence

August 2018
Artificial IntelligencePharmaceutical

Abstract

The recent growth of machine learning applications using artificial intelligence (AI), ranging from drug discovery to improvements in patient care, has coincided with increased investments from pharmaceutical and technology companies. Subsequently, there has been a sharp increase in the number of start-ups in this space along with heightened expectations regarding the implications of AI in the health care industry. Given the strict regulations pertaining to drug development and commercial marketing, there are questions as to whether AI can operate within the contours of existing laws or would require novel legal frameworks. This article makes an effort to address those emerging questions.

PLS LogoCopyright & permissions

Author

Portrait image of Priya Mannan
Priya Mannan
Associate General Counsel, Novartis Institutes for Biomedical Research, USA

Haripriya M. Mannan, Associate General Counsel, NIBRI, Cambridge, MA Priya joined Novartis in June 2009 as Associate General Counsel for the Novartis Institutes of Bio Medical Research, Inc. (“NIBR”) in Cambridge, MA. At NIBR, she is the Global Head of Compliance and manages social media, e-commerce, Big data, clinical, ethical, privacy and regulatory matters. Prior to joining NIBR, Priya was a Senior Counsel At Baxter International Inc., in Deerfield, IL. At Baxter, Priya was an FDA Regulatory and Healthcare Compliance attorney and also managed clinical trials and product promotion for the Bioscience business for the company. Priya’s first in-house position was at Pfizer Inc., where she managed in-licensing of phase II and III compounds followed by Medtronic Inc., where she was responsible for clinical, research & development, regulatory and general legal business transactions. Before joining as in-house counsel, Priya was associated with the firms of Reid & Riege and Cantor Colburn based in Hartford, CT where she practiced Healthcare law. She received her undergraduate degree from Madras University majoring in Bio Chemistry and Chemistry and her first law degree also from Madras University. She also received her JD and LLM degrees from St. Louis University School of Law, St. Louis. Missouri.

Company

Novartis Institutes for Biomedical Research

The Novartis Institutes for BioMedical Research (NIBR) is the innovation engine of Novartis. We collaborate across scientific and organizational boundaries, with a focus on powerful new technologies that have the potential to help produce therapeutic breakthroughs for patients.

Related Papers

“But I Wore the Lemon Juice”: AI, Confidence, Confidentiality, and the Novel Risks Facing In-House Counsel
Contemporary lessons for international in-house counsel can emerge from strange places. In 1995, two Pittsburgh bank robbers applied lemon juice to their faces, confidently believing it would blur their appearance...Read more
Portrait image of Todd Krieger
Todd Krieger
Director of International Transactions and Senior Counsel, InterSystems Corporation, USA
From Gatekeeper to Process Architect: The New Role of In-house Counsel in AI Governance
In an era of accelerated advancement in AI technology, dynamic and variable global legislative approaches to AI risk management, and unrelenting commercial pressure for agile AI adoption, the role of...Read more
Portrait image of Cam-Van (Vannie) Nguyen
Cam-Van (Vannie) Nguyen
Senior Managing Counsel, Office of the Chief Legal & Regulatory Officer, Align Technology, Inc., USA
Portrait image of Karen Jaenike
Karen Jaenike
Legal Director, Strategic Commercial Affairs, Align Technology, Inc., USA
Redefining Confidentiality Contracts as Risk Mitigants for AI-Driven Disclosure
This paper discusses the evolving landscape of confidentiality risks associated with the widespread adoption of artificial intelligence (AI) tools in corporate environments. As organisations increasingly leverage AI, traditional confidentiality mechanisms,...Read more
Portrait image of Omavuaye Akintola
Omavuaye Akintola
Associate General Counsel, Abu Dhabi National Oil Company (ADNOC) P.J.S.C., UAE
Implementing Effective Compliance Programs in Jurisdictions Where the Rule of Law is Weak
Multinational organizations increasingly operate in jurisdictions where the rule of law is weak, inconsistently enforced, or subject to political and economic influence. For pharmaceutical and biotechnology companies, these environments present...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
Portrait image of Valentina Lacerca-Allen
Valentina Lacerca-Allen
Title Marketing/ Communication Specialist, Ethiprax LLC., USA